Abstract: Compute-in-memory (CIM) devices and methods for performing vector-matrix multiplication (VMM) are provided. The disclosed CTM device can include a static random access memory (SRAM) array. The SRAM array can include a plurality of column structures. Each column structure can include eight sub-column structures. Each sub-column structure can include at least one bitcell sharing a pair of a local bitline (LBL) and LBLb that can be connected to a pair of global bitlines (GBL) via switches. Each sub-column comprises at least one NOR gate. An even-numbered bitcell can include a wordline 1 (WL1) for a left access transistors, and an odd-numbered bitcell can include a wordline 2 (WL2) for a right access transistors. Every eight columns (8 columns) can be configured to share a hybrid compressor adder-tree (HCA), followed by a bit-first accumulation (BFA).

Abstract: Microcontroller units and methods for computing performance are provided. The disclosed microcontroller unit can include a central processing unit (CPU) configured to start a computing program, an accelerator comprising an in-memory computing (IMC) macro cluster configured to accelerate at least one layer of a machine learning model, a data memory (DMEM), and a direct memory access (DMA) module configured to transfer a weight data of a layer of a machine learning model from the DMEM to the IMC macro cluster.

Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

Abstract: Trans-activating transcription (TAT) factor peptide oligomers coupled with functional agents can selectively complex to the anionic surface of cancerous cells. The TAT conjugates can be delivered to the locus of the tumors using intra-arterial injection during transient blood flow arrest.

Abstract: An optical apparatus comprising an optical switch array comprising a plurality of optical switches configured to selectively route light through one or more of a plurality of waveguides, a plurality of emitters, wherein at least one emitter of the plurality of emitters is disposed in communication with the one or more of the plurality of waveguides and configured to receive light and cause at least a portion of the light to exit the waveguide, and a lens disposed to receive light exiting the one or more of a plurality of waveguides via the at least one emitter, wherein the lens is configured to direct the received light as an optical output, and wherein the position of the at least one emitter relative to the lens facilitates beam steering of the optical output.

Abstract: The present invention provides a compound having the structure: wherein X1 is N or CR5, wherein R5 is H, OH, halogen or alkyl; X2, X3 and X4 are each independently NH, N, S, O or CR6, wherein each R6 is independently H, OH, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl, —O—(alkyl), —S—(alkyl), —NH2, —NH—(alkyl), —N(alkyl)2 or —CO2H; R1, R2, R3 and R4 are each independently —H, —F, —Cl, —Br, —I, —NO2, —CN, —CF3, —CF2H, —OCF3, -(alkyl), -(haloalkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), heterocycle, heterocycloalkyl, -(alkylheteroalkyl), -(alkylaryl), —OH, —OAc, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), (heteroaryl), —SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —NH-(aryl), —NH-(heteroaryl), —C(O)R7, —S(O)R7, —SO2R7, —NHSO2R7, —OC(O)R7, —SC(O)R7, —NHC(O)R7 or —NHC(S)R7, wherein R7 is, H, —(alkyl), —OH, —O(alkyl), —NH2, —NH(alkyl)

Abstract: The present invention provides a method of treating a subject afflicted with a substance use disorder (SUD) comprising administering to the subject an effective amount of a compound having the structure: wherein A is a ring structure, with or without substitution; X1 is C or N; X2 is N, O, or S; Y1 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y2 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y3 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y4 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y5 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y6 is H, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(haloalkyl), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); ? and ? are each pr

Abstract: A process, composition, and apparatus for carbon dioxide (CO2) sequestration are disclosed. The process includes passing air containing the CO2 through a cyclopropeneimine (CPI)-functionalized material. The composition includes a CPI-functionalized material that reacts with CO2 when mixed with air containing the CO2. The apparatus includes a component for providing a CPI-functionalized material and mixing the material with CO2 gas.

Abstract: Certain embodiments include a method for assisting a clinician in performing a medical procedure on a patient using augmented reality guidance. The method can include obtaining a three-dimensional model of an anatomic part of the patient. The method can also include aligning the three-dimensional model with data to form augmented reality guidance for the medical procedure. In addition, the method can include presenting the augmented reality guidance to the clinician during the medical procedure using an augmented reality three-dimensional display.

Abstract: A non-reciprocal filter with parametric amplification to obtain non-reciprocal propagation of forward and reverse signals is disclosed. The non-reciprocal filter may include two asymmetrical transmission lines and a current source. The filter, when implemented in the acoustics domain using surface acoustic waves (SAW), may operate in a phase-coherent or a phase-incoherent degenerate mode, providing low insertion loss and high decibels of isolation.

Abstract: Described are systems, methods, and devices relating to normothermic extracorporeal support of an organ, tissue, or bioengineered graft comprising cross-circulation (XC) perfusion for prolonged periods (days to weeks) via an XC perfusion circuit in connection with an extracorporeal host (e.g., animal, patient, organ transplant recipient) are disclosed. The XC perfusion circuit comprises auto-regulation of blood flow based on the trans-organ blood pressure difference between arterial and venous pressure. Recipient support enabled 36 h of normothermic perfusion that maintained healthy lungs with no significant changes in physiologic parameters and allowed for the recovery of injured lungs. Extended support enabled multiscale therapeutic interventions in all extracorporeal lungs. Lungs exceeded transplantation criteria.

Abstract: Disclosed are systems, methods, and other implementations, including a method for monitoring and managing battery performance that includes deriving a representation of diffusion overpotential behavior for a lithium-ion battery according to a discrete-time state-space approximation of a convolution-defined diffusion (CDD) model for the lithium-ion battery, and determining behavior of the lithium-ion battery according to the discrete-time state-space approximation of the convolution-defined diffusion (CDD) model for the lithium-ion battery.

Abstract: The presently disclosed subject matter provides techniques for inducing collagen cross-linking in human tissue, such as cartilage, by inducing ionization of the water contained in the tissue to produce free radicals that induce chemical cross-linking in the human tissue. In an embodiment, a femtosecond laser operates at sufficiently low laser pulse energy to avoid optical breakdown of the tissue being treated. In an embodiment, the femtosecond laser operates in the infrared frequency range.

Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).

Abstract: Disclosed are devices, systems, apparatus, methods, products, and other implementations, including a method comprising obtaining, by a device, a combined sound signal for signals combined from multiple sound sources in an area in which a person is located, and applying, by the device, speech-separation processing (e.g., deep attractor network (DAN) processing, online DAN processing, LSTM-TasNet processing, Conv-TasNet processing), to the combined sound signal from the multiple sound sources to derive a plurality of separated signals that each contains signals corresponding to different groups of the multiple sound sources. The method further includes obtaining, by the device, neural signals for the person, the neural signals being indicative of one or more of the multiple sound sources the person is attentive to, and selecting one of the plurality of separated signals based on the obtained neural signals. The selected signal may then be processed (amplified, attenuated).

Abstract: Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof in the sequencing of a nucleic acid.

Abstract: A dual function material is provided that captures carbon dioxide from ambient air, i.e., direct air capture, and converts the CO2 to a desired product such as methane. The material includes a high surface area carrier such as Al2O3 upon which catalysts and alkaline adsorbents are positioned proximate each other. In the presence of reactive gas such as hydrogen, the catalysts reduce the adjacent adsorbents to generate additional active sites and enhance the amount of CO2 captured by the material. Once the material becomes saturated with CO2, hydrogen is reintroduced to reduce the catalyst, such as ruthenium, at which time the adsorbed CO2 can migrate from the adsorbent to the catalyst for catalytic conversion to methane. The materials can be employed in isothermal, cyclic reactor systems where target species are bound and then desorbed to reactivate the material, e.g., bind more target species for desorption and/or conversion to additional product.

Abstract: Method for unified networking for a device in heterogeneous mobile environments includes maintaining and monitoring active network interfaces, managing the location of the device, managing network access security, enabling disruption tolerance support for applications, enabling service sharing and session mobility, managing system parameters for one or more active application sessions, managing storage functionality in one or more memory devices, and maintaining a mapping for one or more flows corresponding to the one or more active application sessions, maintaining one or more policies, and performing flow control decisions based upon the policies using a policy engine. The method can also include monitoring for network events, evaluating whether to perform a handover based upon policies, and providing seamless secure handovers in a heterogeneous mobile environment. A device, non-transitory computer-readable medium, and a system for unified networking are also provided.

Abstract: Anti-annexin A1 antibodies are provided and methods of treating FAP and cancer using Anti-annexin A1 antibodies, antibody fragments or fusion proteins, including bispecific antibodies targeting two different annexin A1 epitopes, are also provided.

Abstract: The present invention provides a compound having the structure: wherein R1 is —(C2-C12 alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl); R2 is H, halogen, —NO2, —CN, —CF3, —CF2H, —CH2OCH3, —CF2CH3, —CF2OCH3, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), -(heterocycle), -(heterocycloalkyl), -(aryl), -(heteroaryl), -(hydroxyalkyl), -(haloalkyl), -(alkylaryl), —OH, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(haloalkyl), —O-(aryl), —O-(heteroaryl), —OCF3, SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —N-(alkyl)2, NH-(aryl), —NH-(heteroaryl), —CO2H, —CO2-(alkyl), —C(O)—NH2, —C(O)—NH-(alkyl), —C(O)—NH-(aryl), —SO2CH3 or —Si(CH3) 3; R3 is —OCH3, —OCH2CH3, —F or —Cl; and R4 is —OCH3, —OCH2CH3 or —SCH3; wherein when R1 is —CH2CH3, R3 is —OCH3, and R4 is —OCH3, then R2 is other than H, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3, —CH2OH, —CH(OH) CH3, —OH, —OCH2CH3, —OCH2CH2CH3, —OCH(CH3)2, —SCH3,